How we do it

The lifelong need for immunosuppression after transplantation negatively affects both patient health and the transplanted organ. ITB-MED’s novel therapy aims to provide immunosuppression freedom, potentially leading to better outcomes, improved quality of life, and reduced healthcare costs.

<p>Jennifer is the first HLA-mismatched patient in the world to successfully receive a kidney transplant where transplantation tolerance was actively induced. She has now lived more than 15 years without having to take any anti-rejection immunosuppression.</p>


Join us now

<p>We’re developing an innovative therapy that would potentially empower transplant patients to reclaim their freedom and quality of life – all without the need for immunosuppressive medications.</p>


How we transform transplantation

Real stories: How our therapy is changing lives

Jennifer Searl

Help us make a real difference